BioNTech (BNTX) Competitors $106.89 -1.06 (-0.98%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$107.00 +0.11 (+0.10%) As of 10/21/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTX vs. GSK, ARGX, TAK, ONC, INSM, TEVA, GMAB, SMMT, ASND, and RDYShould you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. BioNTech vs. Its Competitors GSK argenex Takeda Pharmaceutical BeOne Medicines Insmed Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Do analysts prefer BNTX or GSK? BioNTech currently has a consensus price target of $134.32, suggesting a potential upside of 25.66%. GSK has a consensus price target of $37.38, suggesting a potential downside of 14.92%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts clearly believe BioNTech is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.88 Which has more volatility and risk, BNTX or GSK? BioNTech has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Which has preferable valuation & earnings, BNTX or GSK? GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B8.63-$719.92M-$1.60-66.81GSK$31.63B2.82$3.29B$2.1620.34 Is BNTX or GSK more profitable? GSK has a net margin of 10.81% compared to BioNTech's net margin of -12.20%. GSK's return on equity of 49.22% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% GSK 10.81%49.22%11.31% Do insiders & institutionals hold more shares of BNTX or GSK? 15.5% of BioNTech shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer BNTX or GSK? In the previous week, BioNTech had 1 more articles in the media than GSK. MarketBeat recorded 6 mentions for BioNTech and 5 mentions for GSK. GSK's average media sentiment score of 0.60 beat BioNTech's score of 0.51 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive GSK 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGSK beats BioNTech on 9 of the 16 factors compared between the two stocks. Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTX vs. The Competition Export to ExcelMetricBioNTechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.95B$3.47B$6.21B$10.68BDividend YieldN/A2.27%5.72%4.88%P/E Ratio-66.8123.0629.1527.23Price / Sales8.63480.03578.83130.73Price / CashN/A47.5937.5161.65Price / Book1.2210.6612.386.59Net Income-$719.92M-$52.56M$3.32B$276.14M7 Day Performance2.44%2.64%0.77%-0.72%1 Month Performance8.28%13.86%7.30%2.47%1 Year Performance-3.60%14.85%62.64%33.90% BioNTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTXBioNTech2.5 of 5 stars$106.89-1.0%$134.32+25.7%-4.2%$25.95B$2.98B-66.816,772News CoverageGSKGSK1.8963 of 5 stars$43.67+0.3%$37.38-14.4%+15.1%$88.83B$31.63B20.2268,629Upcoming EarningsDividend CutARGXargenex3.2346 of 5 stars$799.56+0.3%$817.53+2.2%+48.9%$48.93B$3.05B41.001,599TAKTakeda Pharmaceutical2.5309 of 5 stars$13.72+0.0%N/A-0.3%$43.64B$4.48T45.7247,455News CoverageONCBeOne Medicines3.0446 of 5 stars$327.03+2.2%$340.30+4.1%N/A$35.84B$3.81B-189.0311,000Analyst ForecastINSMInsmed3.0677 of 5 stars$163.94+1.0%$149.06-9.1%+128.7%$34.65B$363.71M-28.711,271Analyst ForecastTEVATeva Pharmaceutical Industries3.6315 of 5 stars$20.02-0.1%$25.57+27.8%+4.5%$22.96B$16.63B-125.0936,830Positive NewsGMABGenmab A/S3.8789 of 5 stars$32.68+2.7%$40.80+24.8%+32.3%$20.98B$3.26B16.422,682Short Interest ↑Analyst RevisionSMMTSummit Therapeutics2.8487 of 5 stars$22.93+7.4%$31.29+36.4%-8.6%$17.03B$700K-22.70110Trending NewsEarnings ReportAnalyst ForecastOptions VolumeASNDAscendis Pharma A/S3.0306 of 5 stars$208.43-0.5%$248.29+19.1%+55.9%$12.86B$393.54M-40.391,017RDYDr. Reddy's Laboratories2.8574 of 5 stars$14.36+0.1%$16.95+18.1%-6.4%$11.99B$3.81B21.7527,811Positive News Related Companies and Tools Related Companies GSK Competitors argenex Competitors Takeda Pharmaceutical Competitors BeOne Medicines Competitors Insmed Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTX) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
